Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01733394

Recruitment Status : Completed

First Posted : November 27, 2012

Last Update Posted : July 19, 2017

Sponsor:

Collaborators:

American Epilepsy Society

Epilepsy Foundation

Information provided by (Responsible Party):

Michael Privitera, University of Cincinnati

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	September 26, 2016
Actual Study Completion Date :	September 26, 2016

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ Jr, Jiang W, Jiang X, Switzer RD, Privitera MD. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. JAMA Neurol. 2017 Aug 1;74(8):919-926. doi: 10.1001/jamaneurol.2017.0497.

To Top